PMA device
Coaptite Injectable Implant
Merz North America, Inc. · Agent, Bulking, Injectable For Gastro-Urology Use (LNM, Class III) · First FDA decision Nov 10, 2005, newest Jan 25, 2024Overactive bladder and urinary incontinence
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
1
Naming "Coaptite"
MAUDE reports
25
Brand "Coaptite", since 2015
PubMed studies
19
Mentioning "Coaptite"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Coaptite Injectable Implant
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- Coaptite Injectable ImplantPMA supplement
P040047-S070 · Decided Jan 25, 2024 · 365 days after receipt · Normal 180 Day Track
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- CoaptitePMA supplement
P040047-S052 · Decided Jun 26, 2019 · 170 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
- Coaptite Injectable ImplantPMA supplement
P040047-S046 · Decided Mar 28, 2018 · 167 days after receipt · Normal 180 Day Track No User Fee
Device type: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE (LNM) · GI, Urology & Nephrology
3 more FDA decisions with a free account
Older decisions: P040047
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Coaptite", any status and sponsor, newest update first.
Merz North America, Inc.Not on our public-company list
NCT00996489 · 459 participants · Start Jan 8, 2008 · Primary completion Oct 26, 2015
Device: Coaptite® · For: Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Sites: Wetumpka, Alabama; Surprise, Arizona; Encinitas, California · 20 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Coaptite", and for the whole product code for context.
This brand
25 reports: 1 malfunction, 24 injury, 0 death
Whole product code LNM
544 reports: 170 malfunction, 369 injury, 2 death
Newest reports for this brand
3013840437-2022-00132 · Received Oct 19, 2022
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Urethral Stenosis/Stricture
3013840437-2022-00133 · Received Oct 19, 2022
Device type: Ceramics, Calcium Triphosphate/Hydroxypatite, Non-Load Bearing Uses (LMN)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Calcium Deposits/Calcification
3013840437-2022-00013 · Received Feb 22, 2022
Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Sepsis
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0401-2021 · Started Sep 30, 2020
Reason given: The Instructions for Use (IFU) updated 03/02/2020 does not match data listed in the post-approval study.
Cause as FDA categorized it: Labeling design · Device type: Agent, Bulking, Injectable For Gastro-Urology Use (LNM)
Published research
The most relevant PubMed records for "Coaptite"[tiab]. The summary above synthesizes these.
- Ultrasound Evaluation of the Urethra and Bladder Neck Before and After Transurethral Bulking.
Unger CA, Barber MD, Walters MD · Female Pelvic Med Reconstr Surg · 2016
- Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review.
Hoe V, Haller B, Yao HH, et al. · Neurourol Urodyn · 2021Systematic Review
- Update on Urethral Bulking for Stress Urinary Incontinence in Women.
Zheng Y, Rovner E · Curr Urol Rep · 2022Review
- A comparison of calcium hydroxyapatite and dextranomer/hyaluronic Acid for the endoscopic treatment of vesicoureteral reflux.
Ngo TC, Wong IY, Kennedy WA · Adv Urol · 2013
- Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence.
Mayer RD, Dmochowski RR, Appell RA, et al. · Urology · 2007Multicenter Study, Randomized Controlled Trial
- Urethral bulking agents for female stress urinary incontinence.
Hussain SM, Bray R · Neurourol Urodyn · 2019Review
- [Endoscopic treatment of primary vesicoureteral reflux in childhood. Review of 989 cases in a 9 years period].
Nortes Cano L, Zambudio Carmona G, Guirao Piñera MJ, et al. · Cir Pediatr · 2008English Abstract
- Injectable synthetic calcium hydroxylapatite ceramic microspheres (Coaptite) for passive fecal incontinence.
Ganio E, Marino F, Giani I, et al. · Tech Coloproctol · 2008
- Bulking agent induced early urethral prolapse after distal urethrectomy.
Ko EY, Williams BF, Petrou SP · Int Urogynecol J Pelvic Floor Dysfunct · 2007Case Reports
- Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions.
Alam M, Havey J, Pace N, et al. · J Am Acad Dermatol · 2011Research Support, Non-U.S. Gov't
- Systematic review of perianal implants in the treatment of faecal incontinence.
Hussain ZI, Lim M, Stojkovic SG · Br J Surg · 2011Systematic Review
- Systematic review on the efficacy and safety of injectable bulking agents for passive faecal incontinence.
Luo C, Samaranayake CB, Plank LD, et al. · Colorectal Dis · 2010Systematic Review
Other devices of this type
Also filed under product code LNM.
- Deflux Injectable GelPalette Life Sciences · PMA 2016
- Macroplastique ImplantsUroplasty, LLC · PMA 2023
- Solesta (Injectable Gel)Palette Life Sciences · PMA 2021
- Durasphere Injectable Bulking AgentCarbon Medical Technologies, Inc. · PMA 2026
- Contigen Bard Collagen ImplantAllergan, Inc. · PMA 2009
- Bard Tegress Urethral ImplantC.R. Bard, Inc. · PMA 2006
- Enteryx Procedure KitBoston Scientific Corp · PMA 2005
- Durasphere ExpCarbon Medical Technologies, Inc. · PMA 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.